|1.||Sandset, Per Morten: 15 articles (01/2015 - 06/2003)|
|2.||Iversen, Nina: 11 articles (01/2015 - 01/2002)|
|3.||Brenner, Benjamin: 11 articles (05/2014 - 11/2005)|
|4.||Mast, Alan E: 10 articles (01/2016 - 03/2007)|
|5.||Mousa, Shaker A: 10 articles (01/2010 - 02/2002)|
|6.||Pan, Shuchong: 9 articles (02/2015 - 04/2003)|
|7.||Simari, Robert D: 9 articles (02/2015 - 04/2003)|
|8.||Skretting, Grethe: 9 articles (01/2015 - 06/2010)|
|9.||Nadir, Yona: 9 articles (10/2014 - 11/2005)|
|10.||Maroney, Susan A: 8 articles (06/2015 - 03/2007)|
09/01/2000 - "In experimental models of severe sepsis, treatment with TFPI results in significant reduction in mortality. "
07/01/2001 - "To review the preclinical and clinical evidence that provides the therapeutic rationale for recombinant human tissue factor pathway inhibitor (rTFPI) as a novel treatment for human sepsis. "
11/15/2001 - "The protective effects of TF blockade in sepsis-induced ALI were confirmed by using tissue factor pathway inhibitor. "
05/01/2002 - "Despite showing promise in early human studies, a recently completed phase 3 trial of recombinant tissue factor pathway inhibitor in severe sepsis failed to show a reduction in the primary end point of 28-day all-cause mortality. "
11/01/2001 - "A Phase II trial of the efficacy of TFPI in patients with severe sepsis showed a mortality reduction in TFPI- compared to placebo-treated patients and an improvement of organ dysfunctions. "
05/01/1993 - "These results suggest that TFPI used as a topically applied antithrombotic agent is effective for the prevention of thrombosis in microvascular anastomoses."
01/01/2008 - "Inhibition of the FVII-TF-dependent pathway (TFPI and rFVIIai) has been tried in attempts to prevent thrombosis, with promising results in animal models so far not confirmed in clinical trials."
11/01/2010 - "We evaluated the efficacy of recombinant human tissue factor pathway inhibitor (rhTFPI), an anticoagulant that directly inhibits the extrinsic coagulation pathway, using a rat model of microvenous thrombosis. "
07/01/2005 - "We studied TFPI levels in 397 individuals in 21 Spanish families participating in the Genetic Analysis of Idiopathic Thrombosis (GAIT) study. "
01/01/2003 - "The present study was designed to assess the antithrombotic properties of topically applied TFPI in a model of rabbit arterial thrombosis. "
|3.||Hemophilia A (Haemophilia)
03/01/2013 - "Thus, inhibition of TFPI might be a promising novel treatment approach, especially in haemophilia patients with FVIII inhibitors."
06/14/2012 - "This study suggests that neutralization of TFPI by mAb 2021 may constitute a novel treatment option in hemophilia."
06/14/2012 - "Binding of mAb 2021 to TFPI effectively prevented inhibition of FVIIa/TF/FXa and improved clot formation in hemophilia blood and plasma. "
12/01/2015 - "The method was used to study coagulation in hemophilia after inhibition of tissue factor pathway inhibitor. "
05/01/2015 - "Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial."
04/01/1996 - "The aim of the study was to evaluate whether a two-domain non-glycosylated TFPI (117QTFPI1-161) has a bleeding potential in a rat gastric mucosa model. "
06/01/2015 - "Inhibition of TFPI may be a further potential therapeutic strategy for managing bleeding in this group of patients. "
03/06/2012 - "Interestingly, tail blood loss progressively decreased at doses greater than needed to totally inhibit plasma TFPI, suggesting that inhibition of a sequestered pool of TFPI released at the injury site mitigates bleeding. "
03/06/2012 - "However, total inhibition of intravascular TFPI through injection of anti-TFPI antibody mitigated tail vein bleeding. "
03/06/2012 - "Tfpi(+/-) did not alter the bleeding phenotype of F8(-/-) mice. "
03/27/2001 - "Here we report that, in heritable hyperlipidemic Watanabe rabbits, adenoviral gene transfer of TFPI to balloon-injured atherosclerotic arteries reduced the extent of intimal hyperplasia by 43% (P < 0.05) compared with a control vector used at identical titer (1 x 10(10) plaque-forming units/ml). "
03/27/2001 - "Local gene transfer of tissue factor pathway inhibitor regulates intimal hyperplasia in atherosclerotic arteries."
12/01/2000 - "Inhibition of TF with TFPI has been shown to reduce intimal hyperplasia in experimental models. "
07/01/1997 - "TFPI (reviewed in 52) is currently under clinical investigation as an anticoagulant and its effects on intimal hyperplasia in animal models are being studied. "
10/01/1996 - "Local irrigation with tissue factor pathway inhibitor inhibits intimal hyperplasia induced by arterial interventions."
|3.||Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)
|6.||fibrin fragment D (D-dimer)
|7.||Factor VIIa (Activated Factor VII)
|10.||drotrecogin alfa activated (Xigris)
|1.||Free Tissue Flaps
|2.||Angioplasty (Angioplasty, Transluminal)
|3.||Continuous Ambulatory Peritoneal Dialysis (CAPD)
|5.||Estrogen Replacement Therapy